Clinical trials: Stage 1 Hypertension
Hypertension
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
- Trial name
- NCT06236061
- Testing
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg
- Where
- 43 sites in Japan
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Pulmonary
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
This study is designed to understand the relative bioavailability (proportion of the administered dose that is absorbed into the bloodstream) of several fixed dose combinations (FDCs) tablets of ambrisentan and tadalafil for…
- Trial name
- NCT02688387
- Testing
- FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Hypertension
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety.
- Trial name
- NCT06618079
- Testing
- HUC2-565-A, HUC2-565-A and HUC2-565-B, HUC2-565-B, HUC2-565-A and HUC2-565-B
- Where
- South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
The primary objective of the study is to: Evaluate the safety and tolerability of REGN5381 and REGN9035 administered alone or sequentially.
- Trial name
- NCT05291546
- Testing
- REGN9035, REGN5381
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hypertension (HTN), Healthy Adult Participants
Study of AB-110 in Healthy and Hypertensive Participants
This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with…
- Trial name
- NCT07916961
- Testing
- Active drug
- Where
- New Zealand
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Antlia Bioscience, Inc
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer